GIP: the second incretin hormone, and why adding it to GLP-1 changed the results

Before you read onResearch and educational information for adults, not medical advice. This entry explains one longevity term — what it means, why it matters and what the evidence says — and nothing here diagnoses, treats, cures or prevents any condition. Baseline labs come before anything, and your own physician has the final word. Longevity Bros offers coaching and written research protocols only — we do not sell, supply, source or ship any compound.

What it means

Glucose-dependent insulinotropic polypeptide is a 42-amino-acid hormone released by K-cells in the upper small intestine when fat and carbohydrate arrive. Like GLP-1 it boosts insulin secretion in proportion to glucose. Unlike GLP-1 it does not slow stomach emptying much, acts on fat cells to promote nutrient storage, and has receptors in the brain that reduce nausea and appetite.

In type 2 diabetes the GIP response is blunted, which is why it was long thought a poor drug target. Tirzepatide, a single molecule that activates both receptors, overturned that.

Why it matters for longevity

The dual agonist produced about 5 percentage points more weight loss than semaglutide, with less nausea per kilogram lost. Understanding why — GIP's central anti-nausea effect, its action on fat-cell insulin sensitivity, or simply more receptor signalling — decides what the next generation of incretin drugs looks like.

What the evidence says

SURMOUNT-1 (2022): tirzepatide 15 mg produced 20.9% weight loss over 72 weeks. SURPASS-2 compared it head to head with semaglutide 1 mg in diabetes and found greater HbA1c and weight reductions. A 2025 head-to-head (SURMOUNT-5) at full doses found tirzepatide about 20% versus semaglutide 14%.

GIP on its own does little for weight in humans; GIP antagonists also cause weight loss in animals, which is a paradox still being worked out. The leading explanation is that chronic GIP agonism desensitises the receptor, so agonist and antagonist converge. Long-term outcome data for tirzepatide (SURPASS-CVOT) are expected from 2025.

How to measure or use it

There is no clinical reason to measure GIP; it is a drug-mechanism term, not a biomarker.
The practical questions are the same as for any incretin drug: lean-mass protection with protein and resistance training, a DEXA baseline, and the metabolic panel every three months.
Prescription-only; the dosing schedule is a physician decision.

Tirzepatide (research page) — the dual agonist, what it is studied for
Retatrutide (research page) — the triple agonist that adds glucagon
GLP-1 transition guide — switching, phased

Frequently asked questions

Why does adding GIP cause more weight loss?

Not fully known. GIP reduces nausea centrally, which allows higher GLP-1 dosing, and may add its own appetite and fat-cell effects.

Is tirzepatide better than semaglutide?

For weight loss, yes in head-to-head trials (about 20% versus 14%). Cardiovascular outcome data for tirzepatide are still awaited.

Does GIP make you store fat?

Natural GIP promotes fat storage after meals. Chronic drug agonism seems to do the opposite, probably through receptor desensitisation.

Your own protocol

Want this applied to your own numbers?

Fifteen minutes of intake, your labs, a human-reviewed protocol within about 24 hours, three documents, a free coach call and check-ins through the cycle. €399, follow-up included.

Build my protocol Book a 15-minute call